ArticleFrontiers in endocrinology2025
A machine learning-based model for predicting recurrence in intermediate- and high-risk differentiated thyroid cancer: insights from a retrospective single-center study of 2388 patients.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Prediction models for postoperative recurrence in papillary thyroid carcinoma: a systematic review and critical appraisal.Frontiers in endocrinology · 2026Pooled it
- The role of gut microbiota in thyroid cancer: from pathogenesis to diagnosis and treatment.Journal of endocrinological investigation · 2026Review
- Machine learning prediction of thyroid cancer recurrence for early screening and clinical decision pathways: a retrospective cohort study.Discover oncology · 2026Article
- Article
- Artificial intelligence in thyroid ultrasound: clinical applications and perspectives.Frontiers in endocrinology · 2026Review
- Nomogram for postoperative pathological stratification of ≥0.2 cm clinically significant lymph node metastasis burden in pN1 papillary thyroid carcinoma: development and validation using L2 ridge penalized logistic regression.Frontiers in endocrinology · 2026Article
- Explaining Risk Stratification in Differentiated Thyroid Cancer Using SHAP and Machine Learning Approaches.Biomedicines · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Current guidelines provide a recognized yet broad framework for stratifying recurrence risk in differentiated thyroid cancer (DTC) patients. More precise tools are needed for intermediate- and high-risk groups. This study aims to identify recurrence-associated risk factors and develop a machine learning-based predictive model. Methods: In this retrospective analysis, 2,388 DTC patients were randomly assigned to a training group (1,910 cases) and a validation group (478 cases). Predictive factors were identified using univariate and multivariate analyses. Six machine learning models were trained and validated, with performance evaluated through accuracy, area under the curve, and clinical utility via decision curve analysis. Results: Independent risk factors for recurrence included intraglandular dissemination, total tumor size, bilateral cervical lymph node involvement, and Hashimoto's thyroiditis, while normal/elevated TSH and multifocal nodules were protective. The random forest model demonstrated the best performance (training accuracy: 0.801; validation accuracy: 0.808). A random forest-based online calculator was developed to facilitate individualized risk assessment in clinical settings. Conclusions: The random forest model effectively predicts DTC recurrence, offering a practical tool for individualized risk assessment and aiding clinical decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.